Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

r additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre- clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as amended, and most current Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceutic
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... NEW YORK , May 1, 2015  Shares ... over 70% of their value yesterday following the results ... company,s glaucoma therapy, Rhopressa.  Despite the trial failing to ... indicates that positive results may come from future studies. ... a brief company overview, current pipeline, financial review, analyst ...
(Date:4/30/2015)... 30, 2015 Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its first ... Revenue for the first quarter of 2015 was $116.2 ... quarter of 2014, and down $5.3 million or 4.4% ... quarter 2015 net income as reported in accordance with ...
(Date:4/30/2015)... Diabetes Care ® , Inc. (NASDAQ: TNDM ), a ... and t:flex™ Insulin Pumps, today reported its financial results for ... comparing the first quarter of 2015 to the same period ... million from $8.1 million , t:slim Pump shipments grew ... "Our investment in resources to build the foundation of our ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6
(Date:5/2/2015)... May 02, 2015 “ Peachtree Audio ... monthly Tech Report, which features the latest and coolest ... expert and special reporter for NewsWatch, conducted the review ... audio equipment. , Music is an important part ... be pampered and given the royal treatment. Peachtree Audio ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 ZoomCare, the ... has submitted plans to offer its new healthcare insurance ... The ZOOM+ Personal Health Insurance System is the nation’s ... to enhance human performance. ZOOM+ Personal Health Insurance was ... delivery system that are subject to review and regulation ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... Costa Mesa, CA (PRWEB) May 01, 2015 ... sponsor at the Cerner Southeast Regional User Group (RUG) ... 2015. The Cerner Southeast Regional User Group Conference provides ... access to vendors who support all aspects of electronic ... innovative use of Cerner software applications. , In addition ...
(Date:5/1/2015)... Yorba Linda, CA (PRWEB) May 01, 2015 ... of our genetic makeup and the interplay of genes ... Keeping up with developments can be daunting. , LabRoots, ... sciences and clinical diagnostics professionals, will soon host its ... Genomics. , At BioConference Live Genetics and Genomics ...
Breaking Medicine News(10 mins):Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3
... 50 years medical research has been vetted through the ... reviewers to determine whether work merits publication. A study ... and their influence on journal editors who are the ... not. "Published research is becoming a more ...
... Small study found technique restored some muscle function for months ... in using gene therapy to restore some muscle function in ... is the first time such a feat has been performed ... at the annual meeting of the American Society of Gene ...
... Poorman or ... ... personality Jim “Poorman” Trenton has the wavefront Lasik procedure with Los Angeles Lasik ... most noted for his work on Loveline the nightly radio talk show on KROQ, which ...
... ... visibility at the management and board level , ... MetricStream, Inc., the market leader in enterprise-wide Governance, ... with AEI, an emerging markets energy infrastructure company, to provide MetricStream’s GRC Platform and ...
... program reduced cardiovascular disease-related medical and hospital costs, ... national company with 30,000 employees, developed the program ... cardiovascular disease when compared to national benchmarks and ... time, the program included a variety of interventions, ...
... for these two diseases? Or does diabetes cause processes in the ... still unclear why diabetics have a higher rate of cancer than ... In order to precisely identify the types of cancer in ... colleagues in Sweden and the United States to carry out the ...
Cached Medicine News:Health News:To publish or not to publish? That is the question 2Health News:Gene Therapy Shows Promise for Muscular Dystrophy 2Health News:Gene Therapy Shows Promise for Muscular Dystrophy 3Health News:'Poorman' Has Lasik with Dr. Khanna 2Health News:MetricStream Enters into Agreement to Provide Enterprise Risk Management Software Solution to AEI 2Health News:Increased cancer risk of people with type 2 diabetes 2
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Size 2 dilator. Stainless steel. Round knurled handle with polished finish. Overall length: 4 inches....
The interface spatula can be used when irregular interface adherence occurs. By beginning at the point of a dissected edge and sweeping in uniplanar motion towards the area of adherence, the flap can...
Duckbilled spatula designed to enter a side-port stab incision with tip broad enough to efficiently manipulate the lens nucleus in the anterior chamber. Spatula is useful for rotating and cracking th...
Medicine Products: